FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Anderson Karen M.				3. Issuer Name and Ticker or Trading Symbol <u>Centessa Pharmaceuticals plc</u> [CNTA]				
EY RD, ALTRI X0	NCHAM WA14 2DT	_		theck all applicable) Director X Officer (give title below)	10% Owner Other (specify		Individual or Joint/Grou X Form filed by C	Original Filed (Month/Day/Year) up Filing (Check Applicable Line) ne Reporting Person fore than One Reporting Person
(2000)	(Table L - Nor	-Derivat	ive Securities Beneficially Ow	ned			
1. Title of Security (Instr. 4)			2. A	mount of Securities Beneficially	1		. Nature of Indirect Beneficial Ownership (Instr. 5)	
1. Title of Derivative Security (Instr. 4)			s		ying Derivative	or Exercise	5. Ownership Form: Direct (D) or Indirect (I)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
		Date Ex Exercisable Da		ïtle	Amount or Number of Shares	Derivative Security	(instr. 5)	
	n M. (First) PHARMACEUT EY RD, ALTRI X0 (State) str. 4)	n M. (First) (Middle) PHARMACEUTICALS PLC EY RD, ALTRINCHAM X0 WA14 2DT (State) (Zip) str. 4)	n.M. Statement (Month/Day/Year (First) (Middle) PHARMACEUTICALS PLC 11/30/2022 EY RD, ALTRINCHAM Table I - Nor (State) (Zip) Table I - Nor str. 4) Table I - Nor	Statement (Month/Day/Year) II/30/2022 Statement (Month/Day/Year) Statement (Month/Day/Year) II/30/2022 Statement (Month/Day/Year) II/30/2022 Additional statement (Month/Day/Year) II/30/2022 Additional statement (Month/Day/Year) II/30/2022 Additional statement (Month/Day/Year) II/30/2022 Additional statement (Month/Day/Year) II/30/2022 Additional statement (Month/Day/Year) II/30/2022 Additional statement (Month/Day/Year) II/30/2022 II/30/20	A reporting Feasibility Statement (Month/Day/Year) Centessa Pharmaceuticals plc (First) (Middle) HARMACEUTICALS PLC 11/30/2022 EY RD, ALTRINCHAM Director X0 WA14 2DT (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned (Instr. 4) Statement (Month/Day/Year) Centessa Pharmaceuticals plc 4. Relationship of Reporting Person(s) to Iss (Check all applicable) Director X X0 WA14 2DT (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned (Instr. 4) Cherically Convertible Securities Beneficially Owned (Instr. 4) Statement (Month/Day/Year) Table II - Derivative Securities Beneficially Owned (Instr. 4) Cate Exercisable and Expiration Date (Month/Day/Year) Bate Expiration Date Expiration Date (Month/Day/Year) Date Expiration	Statement (Month/Day/Year) Statement (Month/Day/Year) Centessa Pharmaceuticals plc [CNTA] (First) (Middle) HARMACEUTICALS PLC 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) EY RD, ALTRINCHAM Director 10% Owner X0 WA14 2DT Officer (give title below) Other (specify Chief People Officer X0 WA14 2DT Zable I - Non-Derivative Securities Beneficially Owned str. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership F Table I - Derivative Securities Beneficially Owned (Instr. 4) Centressa Pharmaceuticals plc [CNTA] Centessa Pharmaceuticals plc [CNTA] X0 WA14 2DT Director 10% Owner State (Zip) Table I - Non-Derivative Securities Beneficially Owned Securities Beneficially Owned (Instr. 4) Security (Instr. 4) Cate Exercisable and Expiration Date (Month/Day/Year) Date Expiration Date (Month/Day/Year) Date Expiration	Statement (Month/Day/Year) Statement (Month/Day/Year) Centessa Pharmaceuticals plc [CNTA] (First) (Middle) HARMACEUTICALS PLC 4. Relationship of Reporting Person(s) to Issuer 5 EY RD, ALTRINCHAM Director 10% Owner X0 WA14 2DT Other (specify below) 6 (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned 6 Statement (Month/Day/Year) Table I - Non-Derivative Securities Beneficially Owned State Exercisable and (e.g., puts, calls, warrants, options, convertible securities) Table II - Derivative Securities Underlying Derivative (nstr. 4) Centessa Pharmaceuticals plc [CNTA] Centessa Pharmaceuticals plc [CNTA] Statement (Month/Day/Year) Centessa Pharmaceuticals plc [CNTA] Centessa Pharmaceuticals plc [CNTA] Statement (Month/Day/Year) Centessa Pharmaceuticals plc [CNTA] Table I - Non-Derivative Securities Beneficiall	An regionality in Colorit Statement (Month/Day/Year) Statement (Month/Day/Year) Centessa Pharmaceuticals.plc [CNTA] (First) (Middle) PHARMACEUTICALS PLC 4. Relationship of Reporting Person(s) to Issuer 5. If Amendment, Date of (Check all applicable) Director 10% Owner 10% Owner 5. If Amendment, Date of (Check all applicable) Director 10% Owner 5. If Amendment, Date of (Check all applicable) Director 10% Owner 5. If Amendment, Date of (Check all applicable) Statement (Konth/Day/Year) Table I - Non-Derivative Securities Beneficially Owned 6. Individual or Joint/Grow Str. 4) 2. Amount of Securities Beneficially Owned 3. Ownership Form: [Individual or Indirect (I)] 4. Nature of Indirect Beneficially Owned Every table II - Derivative Securities Beneficially Owned Cancer State and Expiration Amount of Securities Beneficially Owned Certersable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Securities Or Privative Securities Underlying Derivative Securities Or Privative Security (Instr. 4) 4. Conversion or Exercise Privative Security (Instr. 4) 5. Ownership Form: Direct (0) or Indirect (0) (Instr. 5) Security (Instr. 4) Amount or Securities

Explanation of Responses

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

 /s/ Gregory Weinhoff, attorney-in-fact
 12/05/2022

 ** Signature of Reporting Person
 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is field by more than one reporting person, see Instructions (b) (while a more structure).
 ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

** Intentional missiatements of omissions of acts constitute Federal Chininal Violations See 18 0.5.C. 1001 and 15 0.5.C. 781(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

LIMITED POWER OF ATTORNEY

The undersigned hereby constitutes and appoints each of Iqbal Hussain, Gregory Weinhoff, and Richard Menziuso, signing singly, and with fi

(1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Centessa Pharmaceutica.

(2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any

(3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may build undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may a

The undersigned hereby grants to each such attorney-in-fact, acting singly, full power and authority to do and perform any and every act a

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file such forms with respect to foregoing attorneys-in-fact. This Power of Attorney supersedes any prior power of attorney in connection with the undersigned's capacity as a individual attorney-in-fact if such attorney-in-fact ceases to be an employee of the Company.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of November 30, 2022.

/s/ Karen M. Anderson Signature

Karen M. Anderson Print Name